Oncotarget

Reviews:

Associations of the glutathione S-transferase P1 Ile105Val genetic polymorphism with gynecological cancer susceptibility: a meta-analysis

Erjiang Zhao _, Kai Hu and Yan Zhao

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:41734-41739. https://doi.org/10.18632/oncotarget.16764

Metrics: PDF 584 views  |   HTML 863 views  |   ?  


Abstract

Erjiang Zhao1, Kai Hu2 and Yan Zhao1

1 Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou, China

2 Henan Academy of Medical Sciences, Zhengzhou, Henan, China

Correspondence to:

Erjiang Zhao, email:

Keywords: GSTP1, polymorphism, meta-analysis, cervical cancer, endometrial cancer

Received: July 02, 2016 Accepted: March 09, 2017 Published: March 31, 2017

Abstract

The association between the glutathione S-transferase P1 (GSTP1) Ile105Val polymorphism and gynecological cancer susceptibility has been evaluated in many studies. However, the results remain controversial. Thus, this meta-analysis, based on 10 published case-control studies, was designed to clarify the association of the GSTP1 Ile105Val polymorphism with gynecological cancer risk. Our results suggested that there was no significant association between the GSTP1 Ile105Val polymorphism and the risk of gynecological cancer in all genetic models (GG vs. AA: odds ratio [OR] = 1.41, 95% confidence interval [CI] = 0.75-2.26; AG vs. AA: OR = 1.13, 95% CI = 0.74-1.73; AG/GG vs. AA: OR = 1.17, 95% CI = 0.75-1.81; GG vs. AA/AG: OR = 1.38, 95% CI = 0.79-2.42). Similarly, in the subgroup analyses by cancer type, ethnicity, and smoking status, no significant association with any genetic model was observed. In conclusion, the results of our meta-analysis suggest that the GSTP1 Ile105Val polymorphism is not associated with the development of gynecological cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16764